Novoheart is a global stem cell biotechnology brand dedicated to revolutionizing the field of bioartificial human heart engineering. With their expertise in stem cell and bioengineering approaches, Novoheart is committed to creating bioartificial human heart surrogates that can be used for various purposes such as drug discovery, disease modeling, and screening. Their flagship product, the mini-Heart Platform, is a state-of-the-art solution consisting of three advanced engineered-tissue formats made from human stem cell-derived cardiomyocytes.

This platform allows for the assessment of specific cardiac functional outputs, enabling researchers and scientists to evaluate the state of cardiac health more effectively. The success of Novoheart's mini-Heart Platform is evident in their impressive track record, including being the first to genetically engineer human heart cells and create a human mini-heart. With over 25 years of experience in human heart bioengineering and more than 100 peer-reviewed publications, Novoheart is at the forefront of the industry.

By providing cost-effective and time-saving solutions that reduce the dependency on animal testing, Novoheart is changing the course of research and discovery in the field of human heart research. Contact them today to learn more about their innovative products and services